How has our small cap growth-focused Osterweis Opportunity Fund beaten the market? Read a Forbes Daily Cover article to find out about the team’s disciplined valuation approach and why it has served them well over the years.
| Document | Date |
|---|---|
| Shareholder Letter | October 2024 |
| Fact Sheet | September 2024 |
| Document | Date |
|---|---|
| Summary Prospectus | June 2024 |
| Statutory Prospectus | June 2024 |
| Statement of Additional Information | June 2024 |
| Semi-Annual Report | September 2023 |
| Annual Report | March 2024 |
| Proxy Voting Record (N-PX) | June 2024 |
After reading the prospectus, please click on the links below to download an application or open an account online.
| Document | Date |
|---|---|
| Application - Regular Account | |
Regular/Taxable accounts for Individuals, Joint or Gifts to Minors. |
|
| Entity Application - Regular Account | |
Regular/Taxable accounts for entities such as C Corporations, Partnerships, Limited Liability Companies, etc. |
|
| Application - IRA Account | |
Regular, Roth, SEP, SIMPLE, Transfer or Rollover IRA account. Please read the IRA Disclosure Statement & Custodial Agreement. |
|
| IRA or CESA Transfer Form | |
Transfer an existing IRA to the Osterweis Funds. |
|
| Beneficiary Change Form | |
Change your beneficiaries for Traditional, Roth, SEP and SIMPLE IRA’s. |
Jim Callinan was the Co-Founder & Chief Investment Officer at RS Investments. He also co-founded the RS Growth Group LLC in 1996 and managed the RS Emerging Growth Fund from 1996 until 2010. In 1999 Mr. Callinan was named Morningstar’s Domestic Stock Manager of the Year.*
He served as portfolio manager for the Putnam OTC Emerging Growth Fund from 1994 to 1996 and began his career at Putnam Investments as an equity research analyst in 1987. He joined Osterweis Capital Management in 2016 and brought with him the Emerging Growth Partners, LP, a concentrated small cap growth strategy he founded at RS in 2006.
Mr. Callinan is a member of the Weatherbie Capital Advisory Board.
He is an equity owner in the firm and the Lead Portfolio Manager for the small cap growth strategy.
Mr. Callinan graduated from Harvard College (B.A. in Economics), New York University (M.S. in Accounting) and Harvard Business School (M.B.A.). Mr. Callinan holds the CFA designation.
*Morningstar Managers of the Year are determined by a combination of qualitative research by Morningstar’s manager research analysts; risk-adjusted medium- to long-term performance track records; and performance in the calendar year.
Prior to joining Osterweis Capital Management in 2016, Matt Unger spent three years at RS Investments as a Research Associate covering small cap growth companies in the medical technology and industrial sectors. Before graduate school, Matt worked at Platte River Capital covering the medical device sector from 2008-2010.
He is an equity owner in and principal of the firm and a Portfolio Manager for the small cap growth strategy.
Mr. Unger graduated from Trinity University (B.S. in Finance, cum laude) and Southern Methodist University, Cox School of Business (M.B.A.). Mr. Unger holds the CFA designation.
Prior to joining Osterweis Capital Management in 2014, Bryan Wong was a member of the investment team managing the endowment of the David and Lucile Packard Foundation. Before that, Mr. Wong was an Analyst at Wohl Capital Management, a long/short hedge fund.
He is an equity owner in and a principal of the firm and a Portfolio Manager for the small cap growth strategy.
Mr. Wong serves on the investment committee of the Asian Pacific Fund.
Mr. Wong graduated from Yale University (B.A. in Political Science and International Studies with distinction) and the University of California Berkeley, Haas School of Business (M.B.A., Investment Management Fellow). He holds the CFA designation and is a member of the CFA Society of San Francisco.
Prior to joining Osterweis Capital Management in 2023, Jamie Wolf was an Equity Analyst at Invesco LTD covering small, mid, and large cap companies in the consumer sector. Before that, he worked at Haverford Trust Company as a Senior Research Analyst.
Mr. Wolf is a Research Analyst for the small cap growth strategy.
He is a member of the Value Investor Club, LA CFA Society, and American Chemical Society.
Mr. Wolf graduated from Franklin and Marshall College (B.A. in Chemistry and Economics) and UCLA Anderson School of Management (M.B.A.). He holds the CFA designation.
The Fund was rated 4 Stars against 542 funds Overall, 3 Stars against 542 funds over 3 Years, 5 Stars against 521 funds over 5 Years in the Small Growth category based on risk-adjusted returns as of 10/31/24.
The Morningstar Rating™ for funds, or “star rating,” is calculated for mutual funds, variable annuity and variable life subaccounts, exchange-traded funds, closed-end funds, and separate accounts) with at least a three-year history. Exchange-traded funds and open-ended mutual funds are considered a single population for comparative purposes. It is calculated based on a Morningstar Risk-Adjusted Return measure that accounts for variation in a managed product’s monthly excess performance, placing more emphasis on downward variations and rewarding consistent performance. The top 10% of products in each product category receive 5 stars, the next 22.5% receive 4 stars, the next 35% receive 3 stars, the next 22.5% receive 2 stars, and the bottom 10% receive 1 star. The Overall Morningstar Rating for a managed product is derived from a weighted average of the performance figures associated with its three-, five-, and 10-year (if applicable) Morningstar Rating metrics. The weights are: 100% three-year rating for 36-59 months of total returns, 60% five-year rating/40% three-year rating for 60-119 months of total returns, and 50% 10-year rating/30% five-year rating/20% three-year rating for 120 or more months of total returns. While the 10-year overall star rating formula seems to give the most weight to the 10-year period, the most recent three-year period has the greatest impact because it is included in all three rating periods.
The Osterweis Funds are available by prospectus only. The Funds’ investment objectives, risks, charges, and expenses must be considered carefully before investing. The summary and statutory prospectuses contain this and other important information about the Funds. You may obtain a summary or statutory prospectus by calling toll free at (866) 236-0050, or by visiting www.osterweis.com/statpro. Please read the prospectus carefully before investing to ensure the Fund is appropriate for your goals and risk tolerance.
Mutual fund investing involves risk. Principal loss is possible.
The Osterweis Opportunity Fund may invest in unseasoned companies, which involve additional risks such as abrupt or erratic price movements. The Fund may invest in small and mid-sized companies, which may involve greater volatility than large-sized companies. The Fund may invest in IPOs and unseasoned companies that are in the early stages of their development and may pose more risk compared to more established companies. The Fund may invest in ETFs, which involve risks that do not apply to conventional funds. Higher turnover rates may result in increased transaction costs, which could impact performance. From time to time, the Fund may have concentrated positions in one or more sectors subjecting the Fund to sector emphasis risk. The Fund may invest in foreign and emerging market securities, which involve greater volatility and political, economic and currency risks and differences in accounting methods. These risks may increase for emerging markets.
While the fund is no-load, management fees and other expenses still apply. Please refer to the prospectus for more information.
Osterweis Capital Management is the adviser to the Osterweis Funds, which are distributed by Quasar Distributors, LLC.
Get our most recent outlooks and fund updates and receive invitations to our webinars, right in your inbox. Fields marked with an * are required.
We use cookies to make your experience of our website better. We need to ask for your consent to set these cookies. Please note that if you keep browsing this website without electing an option, your consent is deemed to be given.
By clicking "agree" or continuing to browse this website without electing an option, you are also accepting our Privacy Policy.
